e8vk
 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT UNDER SECTION 13 or 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 8, 2003

NOVAVAX, INC.

(Exact name of registrant as specified in its charter)
         
Delaware   0-26770   22-2816046
 
 
(State or other jurisdiction of   (Commission   (I.R.S. Employer
incorporation or organization)   File No.)   Identification No.)
     
8320 Guilford Road, Columbia, MD   21046
 
(Address of principal executive offices)   (Zip code)
 
(301) 854-3900
Registrant’s telephone number, including area code
 
Not applicable
(Former name or former address, if changed since last report)

 

 

NOVAVAX, INC.
ITEMS TO BE INCLUDED IN THIS REPORT

ITEM 5. OTHER EVENTS.

          On August 8, 2003, the Company announced the appointment of Nelson M. Sims as President and Chief Executive Officer and Director of Novavax, Inc.

          A copy of the Press Release is attached hereto as Exhibit 99.1 and incorporated herein by this reference.

ITEM 7. EXHIBITS.

  99.1   Press Release dated August 8, 2003.

2

 

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
        NOVAVAX, INC.
         
Date: August 8, 2003   By:      /s/ Dennis W. Genge
       
           Dennis W. Genge, Vice President and
   Chief Financial Officer/Treasurer

3